海外の治験の状況「前立腺癌」での検索結果
167件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- RANDOMIZED, OPEN LABEL, MULTI-CENTER STUDY COMPARING CABAZITAXEL AT 25 MG/M2 AND AT 20 MG/M² IN COMBINATION WITH PREDNISONE EVERY 3 WEEKS TO DOCETAXEL IN COMBINATION WITH PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER NOT PRETREATED WITH CHEMOTHERAPY
- Australia, Belarus, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, Mexico, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United States
- 2011-05-12
Not Recruiting
- Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
- castration-resistant metastatic prostate cancer. br>MedDRA version: 14.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Korea, Republic of, Mexico, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2008-09-05
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-09-12
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-08-22
Not Recruiting
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
- Metastatic Castration- Resistant Prostate Cancer (mCRPC);C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, Province of China, United Kingdom, United States
- 2014-10-01
Not recruiting
- Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
- Advanced Hormone Dependent Prostate Cancer
- Argentina
- 2013-05-21
Not Recruiting
- A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
- Prostate Cancer # Metastatic # Hormone Refractory;C61 - Malignant neoplasm of prostate
- Brazil, Germany, Hungary, South Africa, Sweden
- 2012-10-18
Authorised
- A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
- Metastatic Castrate-Resistant Prostate Cancer br>MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Costa Rica, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-05-04
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC with Prior Chemotherapy
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15